Esperion Therapeutics Inc... (ESPR)
2.22
-0.02 (-0.89%)
At close: Jan 15, 2025, 9:47 AM
Company Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol.
Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program.
Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Esperion Therapeutics Inc.
| Country | United States |
| IPO Date | Jun 26, 2013 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 240 |
| CEO | Sheldon L. Koenig |
Contact Details
Address: 3891 Ranchero Drive Ann Arbor, Michigan United States | |
| Website | https://www.esperion.com |
Stock Details
| Ticker Symbol | ESPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001434868 |
| CUSIP Number | 29664W105 |
| ISIN Number | US29664W1053 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sheldon L. Koenig | President, Chief Executive Officer & Director |
| Benjamin Halladay M.B.A. | Chief Financial Officer |
| Benjamin O. Looker J.D. | General Counsel & Corporate Secretary |
| Betty Jean Swartz | Chief Business Officer |
| Eric J. Warren R.Ph. | Chief Commercial Officer |
| Glenn P. Brame | Chief Technical Operations Officer |
| Tiffany Aldrich M.B.A. | Associate Director of Corporate Communications |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 4 | Filing |
| Dec 18, 2024 | 8-K | Current Report |
| Dec 13, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 07, 2024 | 10-Q | Quarterly Report |